Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care
While SUD affects people across all demographics, a growing body of research and clinical experience…
While SUD affects people across all demographics, a growing body of research and clinical experience makes one point clear: gender meaningfully influences how substance use develops, how it is experienced, and what supports effective treatment. The post Beyond One-Size-Fits-All: Women, Substance Use, and the Need for Gender-Responsive Care appeared first on MedCity News.
This brief describes the role of Medicaid Fraud Control Units (MFCUs) in program integrity efforts, examines caseload and case outcome data, and current issues facing MFCUs.
[Sponsored] Research from MedCity News and Cotiviti shows robust AI adoption by payers and providers, but what steps are they taking for AI governance and AI weaponized cybersecurity threats? The post Hospital and Payer AI Governance Is at a Crossroads appeared first on MedCity News.
The run-up to the midterm elections is turning into a food fight — literally. The summer was marred by a massive foodborne outbreak that sickened scores of people and the recall of tens of thousands of pounds of imported meat, turning the safety of the U.S. food supply into a topic of national conversation and…
Amye Joseph says America’s political polarization has made it an “interesting time” in her Tennessee household. She and her husband, Charlie, have been married 35 years. She’s a Republican. He’s a Democrat. But their shared disenchantment with profit-driven healthcare has provided a unifying target: pharmacy benefit managers, known as PBMs. The Josephs’ frustration is focused…
Audrey Mann Cronin takes over THCB today and has a THCB Gang special called “The Odyssey of Women’s Health: Journeying into the Midterms – Obstacles, Opportunities and What We Can Expect” The panel is Liz Powell, an attorney and Founder of both G2G Consulting and Women’s Health Advocates, and former Capitol Hill staffer; Dr. Elizabeth…
Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare disease that leads to bone growth in soft tissue. Mirum acquired Atebrioz from Incyte earlier this year. The post Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder…
As AI technology in healthcare becomes more deeply involved in the complex, high-stakes tasks of diagnosis and treatment planning, traditional lines of accountability will become less clear. Where does the buck stop for AI-supported medical care? The post When AI Gets Medicine Wrong, Who’s Liable? appeared first on MedCity News.
As a country, we have developed treatments capable of improving the quality of life and preventing long-term damage for children with rheumatic conditions, yet many children cannot obtain them when they need them most. This needs to change. The post Fifty Years of Pediatric Rheumatology, but Children Still Can’t Access the Treatments They Need appeared…
What are the common reasons that a prototype fails to make the transition? There are several, but they all boil down to early-stage programs ignoring the business problem in favor of the technology problem. The post MedTech Commercialization Gap: Moving Beyond Technical Viability appeared first on MedCity News.